# OnCo record nct03424005 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03424005/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03424005", "NCT03424005" ;
  schema:name "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer"@en ;
  schema:alternateName "Morpheus-panBC"@en ;
  schema:description "A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03424005/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03424005> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2018-03-30" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/selicrelumab/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/pfizer/> .